Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology

Journal of Clinical Oncology

Volumn 31, Issue 18, 2013, Pages 2289-2295

  Bariani, Giovanni M ^a   De Celis Ferrari, Anezka C R ^a   Hoff, Paulo M ^a   Krzyzanowska, Monika K ^b   Riechelmann, Rachel P ^a  

^a Oncology Center Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTHOR; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; COMPARATIVE STUDY; CONFLICT OF INTEREST; CONTROLLED STUDY; DRUG INDUSTRY; EXPERIMENTAL THERAPY; FUNDING; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; MEDICAL LITERATURE; NATIONAL HEALTH ORGANIZATION; NON PROFIT ORGANIZATION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLISHING; SELF REPORT; STUDY DESIGN; METHODOLOGY; MULTIVARIATE ANALYSIS; NEOPLASM; ONCOLOGY; PUBLICATION; STANDARD; STATISTICAL MODEL; STATISTICS; WRITING;

AUTHORSHIP; CLINICAL TRIALS, PHASE III AS TOPIC; CONFLICT OF INTEREST; EDITORIAL POLICIES; HUMANS; LOGISTIC MODELS; MEDICAL ONCOLOGY; MULTIVARIATE ANALYSIS; NEOPLASMS; PERIODICALS AS TOPIC; RESEARCH DESIGN; SELF REPORT;

EID: 84882968646     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.6706     Document Type: Article

References (29)

1. Buchkowsky SS, Jewesson PJ: Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38:579-585, 2004
2. Booth CM, Cescon DW, Wang L, et al: Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 26:5458-5464, 2008
3. Riechelmann RP, Wang L, O’Carroll A, et al: Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. J Clin Oncol 25:4642-4647, 2007
4. George B, Simhan S, Lee JA, et al: Conflicts of interest among articles published in the Journal of Clinical Oncology. J Clin Oncol 25:355s, 2007 (suppl; abstr 6633)
5. Friedberg M, Saffran B, Stinson TJ, et al: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282: 1453-1457, 1999
6. Gardner A: Industry-funded breast cancer trials show more positive results. Int J Health Serv 37:591-593, 2007
7. Peppercorn J, Blood E, Winer E, et al: Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109:1239-1246, 2007
8. Thompson DF: Understanding financial conflicts of interest. N Engl J Med 329:573-576, 1993
9. [No authors listed]: Uniform requirements for manuscripts submitted to biomedical journals: International Committee of Medical Journal Editors. Ann Intern Med 126:36-47, 1997
10. Riechelmann RP, Dounaevskaia V, Taback N, et al: Source of funding, conflict of interest (COI), and the interpretation of cancer clinical trials. J Clin Oncol 25:329s, 2007 (suppl; abstr 6530)
11. Lerner TG, Miranda Mda C, Lera AT, et al: The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials. Contemp Clin Trials 33:1019-1022, 2012
12. Jang S, Chae YK, Majhail NS: Financial conflicts of interest in economic analyses in oncology. Am J Clin Oncol 34:524-528, 2011
13. Valachis A, Polyzos NP, Nearchou A, et al: Financial relationships in economic analyses of targeted therapies in oncology. J Clin Oncol 30:1316-1320, 2012
14. Djulbegovic B, Lacevic M, Cantor A, et al: The uncertainty principle and industry-sponsored research. Lancet 356:635-638, 2000
15. Schneider N: Awareness and management of conflicts of interest. J Public Health 18:597-600, 2010
16. Cohen J: Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70:213-220, 1968
17. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 33:159-174, 1977
18. Boyd EA, Bero LA: Assessing faculty financial relationships with industry: A case study. JAMA 284:2209-2214, 2000
19. Lexchin J, Bero LA, Djulbegovic B, et al: Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 326: 1167-1170, 2003
20. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289:454-465, 2003
21. Rose SL, Krzyzanowska MK, Joffe S: Relationships between authorship contributions and authors’ industry financial ties among oncology clinical trials. J Clin Oncol 28:1316-1321, 2010
22. Kesselheim AS, Lee JL, Avorn J, et al: Conflict of interest in oncology publications: A survey of disclosure policies and statements. Cancer 118:188-195, 2012
23. Journal of the National Cancer Institute: Forms: Conflict of interest. http://www.oxfordjournals.org/our_journals/jnci/for_authors/author_forms.html
24. American Society of Clinical Oncology: ASCO’s Policies and Safeguards for Relationships with Industry. http://www.asco.org/conflictofinterest
25. BBC News US and Canada: GlaxoSmithKline to pay $3bn in US drug fraud scandal. http://www.bbc.co.uk/news/world-us-canada-18673220
26. Hartmann M, Knoth H, Schulz D, et al: Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer 89:1405-1408, 2003
27. Knox KS, Adams JR, Djulbegovic B, et al: Reporting and dissemination of industry versus nonprofit sponsored economic analyses of six novel drugs used in oncology. Ann Oncol 11:1591-1595, 2000
28. Hampson LA, Joffe S, Fowler R, et al: Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol 25:3609-3614, 2007
29. Lexchin J: Those who have the gold make the evidence: How the pharmaceutical industry biases the outcomes of clinical trials of medications. Sci Eng Ethics 18:247-261, 2012